Purchase this article with an account.
M. Goldstein, G. Heilweil, M. Kinori, A. Barak, M. Weissbord, A. Loewenstein; Endophthalmitis Following Intravitreal Injection of Bevacizumab and Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):974.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the incidence and final visual outcome patients with endophthalmitis post bevacizumab and ranibizumab inteavitreal injections.
A total of 844 pateints underwent 2016 intravitreal anti-VEGF injections (bevacizumab 1.25mg/0.05ml, ranibizumab 0.5mg/0.05ml) between 02/2006-11/2007. The medication was given under aseptic conditions with a sterile drape and lid speculum using conjunctival application of 5% povidone-iodine. Topical antibiotics were than administered for 5 days. Patients were instructed to come immediately if visual disturbance, pain, or redness of the eyes was noticed. All cases with post injected endophthlmitis were retrospectively analyzed.
Post injection Endophthalmitis occured in 6 out of 844 patients (0.7%) and 2016 injections (0.29%). The mean time to develop endophthalmitis was 1.9 days (range-1-4 days). 5 out of the 6 (83%) patients regained base line visual acuity after treatment for endophthalmits. Coagulase gram negative pathogens were found in 2 out of 6 eyes while 3 cultures were negative and 1 was positive for streptococcus group D.
the rate of post anti-VEGF injection endophthalmitis in our study is higher than in other previously reported series. The visual outcome of post injection endophthalmitis is favorable compared to endophthalmits secondary to other etiologies
This PDF is available to Subscribers Only